Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.

Osonoi T, Saito M, Tamasawa A, Ishida H, Tsujino D, Nishimura R, Utsunomiya K

PloS one19 Dec 2014Cited by 19 (Europe PMC)

PMID25526642PMCIDPMC4272272DOI10.1371/journal.pone.0113468PepBankPUB-25526642

Summary

The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD). Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD. Hemodialysis was conducted on days 1 and 3. Plasma liraglutide and glucose concentrations were measured by enzyme-linked immunosorbent assay and a continuous glucose monitoring system, respectively. The safety profile of liraglutide was also assessed. Hemodialysis had no effect on the pharmacokinetic parameters of liraglutide in patients with diabetes and ESRD; the maximum plasma concentration (Cmax), tmax, area under the concentration-time curve (AUC), and CL/f were unaltered. Similarly, hemodialysis did not affect the mean or minimum glucose levels, AUC, or duration of hyperglycemia (>180 mg/dL) and hypoglycemia (<70 mg/dL) following liraglutide administration. However, significant increases in mean amplitude of glycemic excursions (MAGE) and standard deviation (SD) as markers of glucose fluctuation, and the maximum glucose level were observed during hemodialysis. No adverse events, including hypoglycemia, were observed after liraglutide injection, either off-hemodialysis (day 2) or on-hemodialysis (day 3). Liraglutide was well tolerated in patients with type 2 diabetes and ESRD undergoing hemodialysis. The present results suggested that hemodialysis did not affect the pharmacokinetic profile of liraglutide or most glycemic indices, with the exception of MAGE, SD, and the maximum glucose level. These results suggested that it may be possible to use liraglutide during hemodialysis for diabetes with ESRD, without dose adjustment. Trial Registration UMIN Clinical Trials Registry (UMIN-CTR) UMIN000010159.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialPharmacokinetics
In Japanese adults with type 2 diabetes and end-stage renal disease, hemodialysis did not change the liraglutide Cmax, tmax, AUC or CL/f.
In plain wordsIn Japanese adults with type 2 diabetes and kidney failure, dialysis did not change how liraglutide moved through the body.
Peptide
Liraglutide
Outcome
No significant changeLiraglutide pharmacokinetics (Cmax, tmax, AUC, CL/f) during hemodialysis
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.6 mg or 0.9 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Hemodialysis had no effect on the pharmacokinetic parameters of liraglutide in patients with diabetes and ESRD; the maximum plasma concentration (Cmax), tmax, area under the concentration-time curve (AUC), and CL/f were unaltered.
1 context sentence(design, population, supporting numbers)
Summary · context
Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD.
Show in the study text Report a problemFND-2552664201
02HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes and end-stage renal disease given liraglutide, hemodialysis did not change mean or minimum glucose, glucose AUC, or duration of hyperglycemia or hypoglycemia.
In plain wordsIn Japanese adults with type 2 diabetes and kidney failure given liraglutide, dialysis did not change average glucose or time with high or low glucose.
Peptide
Liraglutide
Outcome
No significant changeMean and minimum glucose, glucose AUC, hyperglycemia and hypoglycemia duration during hemodialysis
Study
n = 10
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg or 0.9 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Similarly, hemodialysis did not affect the mean or minimum glucose levels, AUC, or duration of hyperglycemia (>180 mg/dL) and hypoglycemia (<70 mg/dL) following liraglutide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD.
Show in the study text Report a problemFND-2552664202
03HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes and end-stage renal disease given liraglutide, MAGE, glucose SD and maximum glucose were significantly higher during hemodialysis.
In plain wordsIn Japanese adults with type 2 diabetes and kidney failure given liraglutide, glucose swings and the highest glucose were larger during dialysis.
Peptide
Liraglutide
Outcome
IncreaseGlucose fluctuation (MAGE, SD) and maximum glucose during hemodialysis
Study
n = 10
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg or 0.9 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
However, significant increases in mean amplitude of glycemic excursions (MAGE) and standard deviation (SD) as markers of glucose fluctuation, and the maximum glucose level were observed during hemodialysis.
1 context sentence(design, population, supporting numbers)
Summary · context
Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD.
Show in the study text Report a problemFND-2552664203
04HumanNon-randomized trialSafety outcome
In Japanese adults with type 2 diabetes and end-stage renal disease, no adverse events, including hypoglycemia, were observed after liraglutide injection on or off hemodialysis.
In plain wordsIn Japanese adults with type 2 diabetes and kidney failure, no side effects, including low blood sugar, were seen after liraglutide injection.
Peptide
Liraglutide
Outcome
No significant changeAdverse events including hypoglycemia
Study
n = 10
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 mg or 0.9 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
No adverse events, including hypoglycemia, were observed after liraglutide injection, either off-hemodialysis (day 2) or on-hemodialysis (day 3).
1 context sentence(design, population, supporting numbers)
Summary · context
Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients with ESRD.
Show in the study text Report a problemFND-2552664204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial page ClinicalTrials.govUpdated 14 Apr 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.